Kairos Pharma, Ltd. 宣布,其针对晚期前列腺癌患者的ENV-105二期临床试验中,安全性数据表现令人鼓舞。该药物与激素疗法联用耐受性优异,未报告任何剂量限制毒性或意外不良事件。中期疗效结果预计将于2025年9月揭晓。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.